Dendritic Cell Vaccine in HIV-1 Infection
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring HIV Infection, Dendritic cell vaccine, Autologous virus, Heat inactivated, HIV Therapeutic Vaccine
Eligibility Criteria
Inclusion Criteria:
- Confirmed HIV infection
- CD4 > 450 x 10 6 /L
- baseline VL >10,000 c/ml before any HAART
- Part I, patients off HAART at least during 6 months
- Part II, Patients on HAART with PVL < 200 copies/ml at least during 6 months
- Written informed consent .
Exclusion Criteria:
- Patients with failure to HAART
- Patients with B or C symptoms (CDC classification 1993).
- Age < 18 years old.
- Pregnant or breastfeeding women
- Patients with baseline creatinin > 2.5 mg/dl
- Patients with baseline GOT/GPT > 250 UI/L
Sites / Locations
- Hospital Clínic
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Active Comparator
Placebo Comparator
Active Comparator
Active Comparator
Placebo Comparator
Pulsed dendritic cells untreated patients
non pulsed dendritic cells untreated patients
pulsed dendritic cell treated patient
pulsed dendritic cell in treated patients
non pulsed dendritic cells
Untreated patients receiving a dendritic cell based vaccine pulsed with autologous heat iactivated virus
treated patients will be immunized with a dendritic cell vaccine pulsed with heat inactivated autologous virus immediately before art interruption
patients will be immunized with a dendritic cell vaccine pulsed with heat inactivted autologous virus immediately after interruption of art